Potential biomarkers for early detection of acute graft-versus-host disease
| Authors | |
|---|---|
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Proteomics : clinical applications. |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.ncbi.nlm.nih.gov/pubmed/22927351 |
| Doi | http://dx.doi.org/10.1002/prca.201100104 |
| Field | Oncology and hematology |
| Keywords | BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; C-REACTIVE PROTEIN; SERUM CYTOKINE LEVELS; NECROSIS-FACTOR-ALPHA; ACUTE GVHD; SOLUBLE INTERLEUKIN-2-RECEPTOR; QUANTITATIVE PROTEOMICS; MAJOR COMPLICATIONS; PLASMA BIOMARKERS |
| Attached files | |
| Description | Acute graft-versus-host disease (aGVHD) is the main complication of allogeneic hematopoietic stem cell transplantation (HCT), resulting in considerable morbidity and mortality. Currently, the diagnosis of aGVHD is largely made based on clinical parameters and invasive biopsies. For the past 20 years, researchers have been trying to find reliable biomarkers to enable early and accurate diagnosis of aGVHD. Although a number of potential aGVHD biomarkers have been published, as yet, no validated diagnostic test is available. Proteomics encompasses a broad range of rapidly developing technologies, which have shown tremendous promise for early detection of aGVHD. In this article, we review the current state of aGVHD biomarker discovery, provide a summary of the key proteins of interest and the most common analytical procedures for the clinic, as well as outlining the significant challenges faced in their use. |
| Related projects: |